Drugs / ChimeriVax™-JE
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT00441259 | Jan 2007 → Feb 2011 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00319592 | May 2005 → Sep 2006 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00982137 | Jul 2004 → Apr 2005 | Japanese encephalitis, yellow fever | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00981175 | Apr 2003 → Jun 2004 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00314145 | Nov 2005 → Jun 2006 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00314132 | Oct 2005 → Nov 2006 | Japanese encephalitis | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChimeriVax-JE | “ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.” NCT00982137 ↗5“ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0” NCT00981175 ↗ |
| Known as | JE-CV | “Subjects will be enrolled by age group and randomised to either ChimeriVax™-JE (JE-CV) or JE Mouse Brain Derived Vaccine (JE-MBDV).” NCT00441259 ↗2“a live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) co-administered with live attenuated yellow fever vaccine” PMID 20864814 ↗ Nov 2010 “live, attenuated Japanese encephalitis chimeric virus vaccine (JE-CV)” PMID 21150279 ↗ Dec 2010 |
| Modality | Vaccine | “a new vaccine to be used for vaccination against Japanese encephalitis” NCT00314132 ↗ |
| Route | Subcutaneous | “0.5 mL, Subcutaneous” NCT00314132 ↗ |